421 related articles for article (PubMed ID: 28666800)
1. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
2. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
3. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
4. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
5. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
[TBL] [Abstract][Full Text] [Related]
6. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
7. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
Lv M; Xue G; Cheng H; Meng P; Lian X; Hölscher C; Li D
Brain Behav; 2021 Aug; 11(8):e2231. PubMed ID: 34125470
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
Zhang L; Zhang L; Li L; Hölscher C
Neuropeptides; 2018 Oct; 71():70-80. PubMed ID: 30017231
[TBL] [Abstract][Full Text] [Related]
10. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
Li Y; Liu W; Li L; Hölscher C
Eur J Pharmacol; 2017 Feb; 797():162-172. PubMed ID: 27913104
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
[TBL] [Abstract][Full Text] [Related]
12. The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury.
Bai B; Li D; Xue G; Feng P; Wang M; Han Y; Wang Y; Hölscher C
Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):333-343. PubMed ID: 33500109
[TBL] [Abstract][Full Text] [Related]
13. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Li Y; Liu W; Li L; Hölscher C
Neuropharmacology; 2016 Feb; 101():255-63. PubMed ID: 26453962
[TBL] [Abstract][Full Text] [Related]
15. The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model.
Tian MJ; Wang RF; Hölscher C; Mi RL; Yuan ZY; Li DF; Xue GF
Epilepsy Res; 2019 Aug; 154():97-106. PubMed ID: 31121474
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Zhang Y; Chen Y; Li L; Hölscher C
Behav Brain Res; 2015 Oct; 293():107-13. PubMed ID: 26187689
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Zhang Z; Hao L; Shi M; Yu Z; Shao S; Yuan Y; Zhang Z; Hölscher C
J Parkinsons Dis; 2021; 11(2):529-543. PubMed ID: 33523018
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
Zhang L; Zhang L; Li L; Hölscher C
J Parkinsons Dis; 2019; 9(1):157-171. PubMed ID: 30741689
[TBL] [Abstract][Full Text] [Related]
19. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
Yang X; Feng P; Ji R; Ren Y; Wei W; Hölscher C
Expert Opin Ther Targets; 2022 May; 26(5):445-460. PubMed ID: 35584372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
